a Department of Blood Transfusion , The Third Xiangya Hospital, Central South University , Changsha , China.
b Department of Transfusion Medicine, Laboratory of Platelet and Endothelium Biology , Wuhan Hospital of Traditional Chinese and Western Medicine, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China.
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):968-979. doi: 10.1080/21691401.2019.1584110.
Conventional anti-tumour chemotherapy is facing the challenges of poor specificity, high toxicity and drug resistance. Tumour microenvironment (TME) plays a critical role in tumour development and drug resistance. To address this problem, we constructed a novel anti-tumour nanoparticle platform RBC@BPQDs-DOX/KIR, black phosphorus nanoparticle quantum dots (BPQDs) with one of the chemotherapeutics (doxorubicin, DOX) and an anti-inflammatory traditional Chinese medicine active component (Kirenol, KIR). Red blood cell membrane (RBCm) vesicles were used as the shell to envelop several nanocores. The combination of DOX and KIR may promote therapeutic efficacy, at which the anti-apoptotic effect of the tumour cells was inhibited (by downregulating Bcl-2 and upregulating Bax) and the tumour progression-related inflammatory factors, such as tumour necrosis factor α (TNF-α) and interleukin-6 (IL-6) were downregulated. Furthermore, TME was remodelled and the anti-tumour effect of DOX was magnified. RBCm imparts high biocompatibility and enhanced permeability and retention (EPR) effects to RBC@BPQDs-DOX/KIR, thus enhancing its tumour passively targetability. Overall, the RBCm-camouflaged drug delivery system RBC@BPQDs-DOX/KIR as a promising therapy for targeted chemotherapeutics and anti-inflammatory therapeutics may provide a specific and highly efficient anti-tumour treatment choice.
传统的抗肿瘤化疗面临着特异性差、毒性高和耐药性等问题。肿瘤微环境（TME）在肿瘤的发生和耐药性中起着关键作用。为了解决这个问题，我们构建了一种新型的抗肿瘤纳米粒子平台 RBC@BPQDs-DOX/KIR，它将一种化疗药物（阿霉素，DOX）和一种抗炎中药活性成分（刺蒺藜皂苷，KIR）负载到黑磷量子点（BPQDs）上。红细胞膜（RBCm）囊泡被用作外壳来包裹几个纳米核。DOX 和 KIR 的结合可能会促进治疗效果，抑制肿瘤细胞的抗凋亡作用（通过下调 Bcl-2 和上调 Bax），下调肿瘤进展相关的炎症因子，如肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）。此外，TME 被重塑，DOX 的抗肿瘤作用被放大。RBCm 赋予 RBC@BPQDs-DOX/KIR 高生物相容性和增强的通透性和保留（EPR）效应，从而增强其肿瘤被动靶向性。总之，作为一种有前途的靶向化疗和抗炎治疗药物，RBCm 伪装的药物传递系统 RBC@BPQDs-DOX/KIR 可能为特异性和高效的抗肿瘤治疗提供一种选择。
